Description
This assay uses the Luminex® 200™ platform.
Consider our assay for an in-depth analysis of 21 essential T-cell biomarkers. The Human High Sensitivity T-Cell Expanded Panel 21-Plex Discovery Assay® Array (HDHSTC21) includes key cytokines such as IL-6, IL-17A, and TNFα, providing detailed insights into T-cell mediated immune responses and inflammatory pathways.
Low levels of inflammation are associated with various clinical and sub-clinical diseases, including autoimmune disorders, cardiovascular conditions, diabetes, neurological diseases, cancer and chronic infection. Measuring cytokines at picogram concentrations is crucial for understanding the development and progression of these conditions. For instance, IL-17A and TNFα are critical in studying autoimmune diseases like rheumatoid arthritis and psoriasis, while IL-10 and IL-12p70 play roles in immune regulation and inflammatory responses.
Our assay is also ideal for scenarios where sample volume is limited but high sensitivity is required. With finely tuned detection capabilities in the picogram range, it allows for sample dilution without sacrificing sensitivity, ensuring accurate and reliable results even with constrained volumes.
For even more delicate concentration trends, such as those in the femtogram range, or when working with very limited sample volumes and picogram-level expectations, consider our Human MSD® Discovery Assay® ULTRA HIGH Sensitivity Cytokine Array (MSDUHS). This array offers the highest sensitivity available for precise and accurate cytokine measurement.
Click here for information on shipping biological samples for Discovery Assays
Published Research Featuring Our HDHSTC21 (HDHSTC14):
-
- Henderson, J. D., Quigley, S. N. Z., Chachra, S. S., Conlon, N., & Ford, D. (2024). The use of a systems approach to increase NAD+ in human participants. npj Aging, 10, Article 7.
- Wang, M., Wisniewski, C. A., Xiong, C., Chhoy, P., Goel, H. L., Kumar, A., Zhu, L. J., Li, R., St. Louis, P. A., Ferreira, L. M., Pakula, H., Xu, Z., Loda, M., Jiang, Z., Brehm, M. A., & Mercurio, A. M. (2023). Therapeutic blocking of VEGF binding to neuropilin-2 diminishes PD-L1 expression to activate antitumor immunity in prostate cancer. Science Translational Medicine, 15(694).
- Russo, M. A., Georgius, P., Staats Pires, A., Heng, B., Allwright, M., Guennewig, B., Santarelli, D. M., Bailey, D., Fiore, N. T., Tan, V. X., Latini, A., Guillemin, G. J., & Austin, P. J. (2020). Novel immune biomarkers in complex regional pain syndrome. Journal of Neuroimmunology, 347, 577330.